Literature DB >> 3410664

In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation.

J I Brodfüehrer1, D J Moore, D C Melder, T J Wilke, G Powis.   

Abstract

The antitumor drug pyrazine-2-diazohydroxide exhibits cytotoxicity to A204 tumor cells in vitro under acid conditions. The IC50 with a 1 hr drug exposure at pH of 7.4 was 61 micrograms/ml and at pH of 6.0 it was 31 micrograms/ml. It is suggested that the increased cytotoxicity is due to the acid catalyzed formation of a reactive pyrizinyldiazonium ion from pyrazine-2-diazohydroxide. Pyrazine-2-diazohydroxide is also more cytotoxic to A204 cells under hypoxic conditions in the presence of glucose with an IC50 at pH 7.4 of 22 micrograms/ml. The increased cytotoxicity of pyrazine-2-diazohydroxide under acid and hypoxic conditions may favor selective toxicity to solid tumors in vivo. Coincubation with rat hepatic microsomes increased the cytotoxicity of pyrazine-2-diazohydroxide to A204 cells. The effect did not require NADPH and was not due to formation of metabolites. There was an increased rate of degradation of pyrazine-2-diazohydroxide in the presence of microsomes, presumably with formation of the pyrizinyldiazonium ion. The final degradation product 2-hydroxypyrazine was not cytotoxic to A204 cells. The effect of microsomes on pyrazine-2-diazohydroxide cytotoxicity is probably of little in vivo significance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410664     DOI: 10.1007/bf00170773

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  13 in total

1.  In vivo utilization of oxygen and glucose by neoplastic tissue.

Authors:  P M Gullino
Journal:  Adv Exp Med Biol       Date:  1976       Impact factor: 2.622

2.  Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines.

Authors:  G Powis; E M Hodnett; K S Santone; K L See; D C Melder
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

3.  Modifications of the acid-base status of the internal milieu of tumors.

Authors:  P M Gullino; F H Grantham; S H Smith; A C Haggerty
Journal:  J Natl Cancer Inst       Date:  1965-06       Impact factor: 13.506

Review 4.  Metabolic regulation via intracellular pH.

Authors:  W B Busa; R Nuccitelli
Journal:  Am J Physiol       Date:  1984-04

5.  Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma.

Authors:  P W Vaupel; S Frinak; H I Bicher
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

6.  Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog.

Authors:  D J Moore; J I Brodfuehrer; T J Wilke; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Coordinate regulation of glycolysis by hypoxia in mammalian cells.

Authors:  E D Robin; B J Murphy; J Theodore
Journal:  J Cell Physiol       Date:  1984-03       Impact factor: 6.384

8.  Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma.

Authors:  T J Wilke; K L Kooistra; D J Moore; G Powis
Journal:  J Chromatogr       Date:  1986-11-28

9.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data.

Authors:  J E Moulder; S Rockwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-05       Impact factor: 7.038

10.  pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells.

Authors:  K A Kennedy; J D McGurl; L Leondaridis; O Alabaster
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

View more
  6 in total

1.  Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

Authors:  S D Harrison; J Plowman; D J Dykes; W R Waud; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer.

Authors:  M J Edelman; F J Meyers; T Grennan; J Lauder; J Doroshow
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

3.  Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.

Authors:  M V Dhodapkar; R L Richardson; J M Reid; M M Ames
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

5.  A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.

Authors:  Robert P Whitehead; Joseph M Unger; Lawrence E Flaherty; Eric H Kraut; Glenn M Mills; Catherine E Klein; Robert A Chapman; Gary C Doolittle; Neel Hammond; Vernon K Sondak
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.651

6.  Corticomuscular control of walking in older people and people with Parkinson's disease.

Authors:  Luisa Roeder; Tjeerd W Boonstra; Graham K Kerr
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.